Incyte (NASDAQ: INCY) announced three executive appointments as part of a reorganization of its leadership structure, according to a company statement.

Pablo J. Cagnoni has been named President of Incyte and Global Head of Research and Development. Cagnoni will retain his research and development responsibilities while taking on enterprise-wide strategic planning and operational execution duties.

Steven Stein has been appointed Executive Vice President, Chief Medical Officer and Head of Late-stage Development. Stein will continue overseeing the company's late-stage development programs across hematology, oncology and immunology, as well as global medical affairs.

Mohamed Issa has been named Executive Vice President and Head of U.S. Commercial. Issa will oversee the U.S. oncology business while assuming expanded responsibility for U.S. immunology. The company said these business units will be integrated into a single U.S. commercial organization.

"These appointments reflect the significant contributions Pablo, Steven and Mohamed have made to Incyte and the value they continue to bring to the company," said Bill Meury, Chief Executive Officer of Incyte. "Additionally, we are confident that integrating our U.S. commercial teams into one organization will drive effective launch execution and position Incyte for long-term success."

As part of the transition, Matteo Trotta, Executive Vice President and General Manager of U.S. Dermatology, will leave Incyte following a transition period.

The biopharmaceutical company operates across hematology, oncology, and inflammation and autoimmunity therapeutic areas.